Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition-Reference-Cited by-同舟云学术

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition

Published:2023-07-17 Issue:1 Volume:12 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

van den Ende Tom¹²^ORCID,Ezdoglian Aiarpi³⁴⁵,Baas Lisanne M.³⁵,Bakker Joyce³⁵,Lougheed Sinéad M.³⁵,Harrasser Micaela³⁵⁶,Waasdorp Cynthia⁵⁶⁷,van Berge Henegouwen Mark I.⁸⁹,Hulshof Maarten C.C.M.⁹¹⁰,Haj Mohammad Nadia¹¹,van Hillegersberg Richard¹²,Mook Stella¹³,van der Laken Conny J.⁴,van Grieken Nicole C.T.⁵¹⁴,Derks Sarah³⁵⁶,Bijlsma Maarten F.⁵⁶⁷,van Laarhoven Hanneke W.M.¹²,de Gruijl Tanja D.³⁵

Affiliation:

1. Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

2. Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands

3. Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

4. Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands

5. Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands

6. Oncode Institute, Utrecht, The Netherlands

7. Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

8. Department of Surgery, Amsterdam Umc, University of Amsterdam, Amsterdam, The Netherlands

9. Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands

10. Department of Radiotherapy, Amsterdam Umc, University of Amsterdam, Amsterdam, The Netherlands

11. Department of Medical Oncology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands

12. Department of Surgery, UMC Utrecht, Utrecht University, Utrecht, The Netherlands

13. Department of Radiotherapy, UMC Utrecht, Utrecht University, Utrecht, The Netherlands

14. Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Funder

funded by Hoffmann-La Roche Ltd

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2233403

Reference53 articles.

1. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

2. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

3. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

4. Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

5. Predictive value of radiological response, pathological response and relapse-free survival for overall survival in neoadjuvant immunotherapy trials: pooled analysis of 29 clinical trials